London: A new clinical research study at Roswell Park Cancer Institute (RPCI) will evaluate the safety and efficacy of a novel immunotherapy approach towards curing advanced melanoma.Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.John M. Kane III, MD, FACS, a surgical oncologist who is Chief of the Melanoma/Sarcoma Service at RPCI, will lead the phase I clinical trial, which will enroll between 12 and 20 patients over the course of approximately three years. Participating patients with advanced melanoma will receive a series of three vaccinations over six weeks.
Pak envoy Abdul Basit defends meeting separatists
Imran Khan, Qadri march into Islamabad`s `red zone`
Varanasi: PM Modi`s mini PMO to be inaugurated
PM Narendra Modi addresses DRDO scientists, stresses on innovation and technology